nodes	percent_of_prediction	percent_of_DWPC	metapath
Scopolamine—SI—nervous system—Gilles de la Tourette syndrome	0.0459	0.135	CbGeAlD
Scopolamine—SI—central nervous system—Gilles de la Tourette syndrome	0.0442	0.13	CbGeAlD
Scopolamine—SI—brain—Gilles de la Tourette syndrome	0.0351	0.103	CbGeAlD
Scopolamine—CHRM4—nervous system—Gilles de la Tourette syndrome	0.0227	0.0665	CbGeAlD
Scopolamine—CHRM4—central nervous system—Gilles de la Tourette syndrome	0.0218	0.064	CbGeAlD
Scopolamine—CHRM5—nervous system—Gilles de la Tourette syndrome	0.0177	0.052	CbGeAlD
Scopolamine—CHRM4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0176	0.0267	CbGpPWpGaD
Scopolamine—CHRM4—brain—Gilles de la Tourette syndrome	0.0173	0.0508	CbGeAlD
Scopolamine—CHRM5—central nervous system—Gilles de la Tourette syndrome	0.0171	0.05	CbGeAlD
Scopolamine—CHRM5—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0168	0.0256	CbGpPWpGaD
Scopolamine—CHRM4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.015	0.0228	CbGpPWpGaD
Scopolamine—CHRM4—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0146	0.0221	CbGpPWpGaD
Scopolamine—CHRM5—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0144	0.0218	CbGpPWpGaD
Scopolamine—CHRM5—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0139	0.0212	CbGpPWpGaD
Scopolamine—CHRM4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0136	0.0206	CbGpPWpGaD
Scopolamine—CHRM5—brain—Gilles de la Tourette syndrome	0.0136	0.0397	CbGeAlD
Scopolamine—CHRM5—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.013	0.0197	CbGpPWpGaD
Scopolamine—CHRM4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0126	0.0191	CbGpPWpGaD
Scopolamine—CHRM4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0122	0.0186	CbGpPWpGaD
Scopolamine—CHRM2—nervous system—Gilles de la Tourette syndrome	0.0122	0.0357	CbGeAlD
Scopolamine—CHRM5—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0121	0.0183	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0119	0.018	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0118	0.0179	CbGpPWpGaD
Scopolamine—CHRM5—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0117	0.0178	CbGpPWpGaD
Scopolamine—CHRM2—central nervous system—Gilles de la Tourette syndrome	0.0117	0.0344	CbGeAlD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0117	0.0178	CbGpPWpGaD
Scopolamine—CHRM4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0114	0.0173	CbGpPWpGaD
Scopolamine—CHRM1—nervous system—Gilles de la Tourette syndrome	0.0111	0.0325	CbGeAlD
Scopolamine—CHRM5—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0109	0.0166	CbGpPWpGaD
Scopolamine—CHRM1—central nervous system—Gilles de la Tourette syndrome	0.0107	0.0313	CbGeAlD
Scopolamine—CHRM1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0101	0.0153	CbGpPWpGaD
Scopolamine—CHRM3—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0101	0.0153	CbGpPWpGaD
Scopolamine—CHRM2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00998	0.0151	CbGpPWpGaD
Scopolamine—CHRM3—nervous system—Gilles de la Tourette syndrome	0.00991	0.0291	CbGeAlD
Scopolamine—CHRM1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00982	0.0149	CbGpPWpGaD
Scopolamine—CHRM3—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00978	0.0148	CbGpPWpGaD
Scopolamine—CHRM2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00969	0.0147	CbGpPWpGaD
Scopolamine—CHRM3—central nervous system—Gilles de la Tourette syndrome	0.00954	0.028	CbGeAlD
Scopolamine—CHRM4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0095	0.0144	CbGpPWpGaD
Scopolamine—CHRM2—brain—Gilles de la Tourette syndrome	0.0093	0.0273	CbGeAlD
Scopolamine—CHRM1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00914	0.0139	CbGpPWpGaD
Scopolamine—CHRM3—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00912	0.0138	CbGpPWpGaD
Scopolamine—CHRM5—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0091	0.0138	CbGpPWpGaD
Scopolamine—CHRM2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00903	0.0137	CbGpPWpGaD
Scopolamine—CHRM1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0085	0.0129	CbGpPWpGaD
Scopolamine—CHRM3—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00847	0.0129	CbGpPWpGaD
Scopolamine—CHRM1—brain—Gilles de la Tourette syndrome	0.00847	0.0248	CbGeAlD
Scopolamine—CHRM2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00839	0.0127	CbGpPWpGaD
Scopolamine—CHRM1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00825	0.0125	CbGpPWpGaD
Scopolamine—CHRM3—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00822	0.0125	CbGpPWpGaD
Scopolamine—CHRM2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00815	0.0124	CbGpPWpGaD
Scopolamine—CHRM4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00798	0.0121	CbGpPWpGaD
Scopolamine—CHRM1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00769	0.0117	CbGpPWpGaD
Scopolamine—CHRM3—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00766	0.0116	CbGpPWpGaD
Scopolamine—CHRM5—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00765	0.0116	CbGpPWpGaD
Scopolamine—CHRM2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00759	0.0115	CbGpPWpGaD
Scopolamine—CHRM3—brain—Gilles de la Tourette syndrome	0.00758	0.0222	CbGeAlD
Scopolamine—SI—Metabolism—HDC—Gilles de la Tourette syndrome	0.00751	0.0114	CbGpPWpGaD
Scopolamine—CHRM1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0064	0.00972	CbGpPWpGaD
Scopolamine—CHRM3—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00638	0.00969	CbGpPWpGaD
Scopolamine—CHRM2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00632	0.00959	CbGpPWpGaD
Scopolamine—CHRM1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00538	0.00817	CbGpPWpGaD
Scopolamine—CHRM3—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00537	0.00814	CbGpPWpGaD
Scopolamine—CHRM2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00531	0.00806	CbGpPWpGaD
Scopolamine—ABCB1—midbrain—Gilles de la Tourette syndrome	0.00469	0.0138	CbGeAlD
Scopolamine—CHRM3—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00448	0.00679	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00443	0.00673	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.00435	0.0066	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0043	0.00653	CbGpPWpGaD
Scopolamine—ABCB1—nervous system—Gilles de la Tourette syndrome	0.00386	0.0113	CbGeAlD
Scopolamine—ABCB1—central nervous system—Gilles de la Tourette syndrome	0.00371	0.0109	CbGeAlD
Scopolamine—CHRM4—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00312	0.00473	CbGpPWpGaD
Scopolamine—CHRM4—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00303	0.00459	CbGpPWpGaD
Scopolamine—ABCB1—brain—Gilles de la Tourette syndrome	0.00295	0.00864	CbGeAlD
Scopolamine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00289	0.00439	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00284	0.0043	CbGpPWpGaD
Scopolamine—CHRM4—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00282	0.00428	CbGpPWpGaD
Scopolamine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00281	0.00426	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00281	0.00426	CbGpPWpGaD
Scopolamine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00277	0.00421	CbGpPWpGaD
Scopolamine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00269	0.00408	CbGpPWpGaD
Scopolamine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00262	0.00397	CbGpPWpGaD
Scopolamine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00251	0.0038	CbGpPWpGaD
Scopolamine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00248	0.00376	CbGpPWpGaD
Scopolamine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00241	0.00365	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.00238	0.00362	CbGpPWpGaD
Scopolamine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00237	0.0036	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.00231	0.00351	CbGpPWpGaD
Scopolamine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00231	0.0035	CbGpPWpGaD
Scopolamine—CHRM5—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00227	0.00345	CbGpPWpGaD
Scopolamine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00224	0.0034	CbGpPWpGaD
Scopolamine—CHRM1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.00215	0.00327	CbGpPWpGaD
Scopolamine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00215	0.00326	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00208	0.00315	CbGpPWpGaD
Scopolamine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00203	0.00308	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00201	0.00306	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00195	0.00296	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00195	0.00295	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00193	0.00292	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00189	0.00287	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00189	0.00287	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00189	0.00287	CbGpPWpGaD
Scopolamine—CHRM2—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00188	0.00285	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00187	0.00284	CbGpPWpGaD
Scopolamine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00183	0.00278	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00183	0.00278	CbGpPWpGaD
Scopolamine—CHRM2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00182	0.00277	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00181	0.00274	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00176	0.00268	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00176	0.00267	CbGpPWpGaD
Scopolamine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00176	0.00266	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00176	0.00266	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00174	0.00264	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00171	0.00259	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00167	0.00254	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00167	0.00253	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00165	0.0025	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00164	0.00248	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00162	0.00246	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00162	0.00246	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0016	0.00243	CbGpPWpGaD
Scopolamine—CHRM1—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.0016	0.00243	CbGpPWpGaD
Scopolamine—CHRM3—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00159	0.00242	CbGpPWpGaD
Scopolamine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00157	0.00238	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00151	0.00229	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00151	0.00229	CbGpPWpGaD
Scopolamine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.0015	0.00228	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00149	0.00226	CbGpPWpGaD
Scopolamine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00143	0.00217	CbGpPWpGaD
Scopolamine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00143	0.00216	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00127	0.00193	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00127	0.00193	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00126	0.00191	CbGpPWpGaD
Scopolamine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00124	0.00188	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00124	0.00188	CbGpPWpGaD
Scopolamine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00123	0.00187	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00123	0.00187	CbGpPWpGaD
Scopolamine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00122	0.00185	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00122	0.00185	CbGpPWpGaD
Scopolamine—CHRM3—Metabolism—HDC—Gilles de la Tourette syndrome	0.00122	0.00185	CbGpPWpGaD
Scopolamine—CHRM4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.0012	0.00181	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00115	0.00175	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00115	0.00174	CbGpPWpGaD
Scopolamine—CHRM5—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00115	0.00174	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00114	0.00172	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00107	0.00162	CbGpPWpGaD
Scopolamine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00106	0.00161	CbGpPWpGaD
Scopolamine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00106	0.0016	CbGpPWpGaD
Scopolamine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00105	0.00159	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00104	0.00157	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00102	0.00155	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000992	0.00151	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000969	0.00147	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000965	0.00146	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000941	0.00143	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000928	0.00141	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000924	0.0014	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000901	0.00137	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000876	0.00133	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000839	0.00127	CbGpPWpGaD
Scopolamine—CHRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000806	0.00122	CbGpPWpGaD
Scopolamine—CHRM3—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000804	0.00122	CbGpPWpGaD
Scopolamine—CHRM2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000796	0.00121	CbGpPWpGaD
Scopolamine—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000772	0.00117	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000719	0.00109	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000717	0.00109	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00071	0.00108	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000698	0.00106	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000696	0.00106	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000689	0.00105	CbGpPWpGaD
Scopolamine—CHRM4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000676	0.00103	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000653	0.000991	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000651	0.000988	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000651	0.000987	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000649	0.000984	CbGpPWpGaD
Scopolamine—CHRM5—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000647	0.000982	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000645	0.000979	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000642	0.000975	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000634	0.000963	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000632	0.000959	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000626	0.00095	CbGpPWpGaD
Scopolamine—CHRM4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000614	0.000931	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000591	0.000897	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000589	0.000894	CbGpPWpGaD
Scopolamine—CHRM5—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000588	0.000892	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000583	0.000885	CbGpPWpGaD
Scopolamine—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000574	0.000871	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000572	0.000869	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000556	0.000843	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000548	0.000832	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000532	0.000808	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000518	0.000786	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000496	0.000752	CbGpPWpGaD
Scopolamine—CHRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000456	0.000692	CbGpPWpGaD
Scopolamine—CHRM3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000454	0.000689	CbGpPWpGaD
Scopolamine—CHRM2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00045	0.000683	CbGpPWpGaD
Scopolamine—CHRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000414	0.000628	CbGpPWpGaD
Scopolamine—CHRM3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000413	0.000626	CbGpPWpGaD
Scopolamine—CHRM2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000408	0.00062	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000386	0.000586	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000385	0.000584	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000381	0.000578	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000375	0.000569	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000373	0.000567	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00037	0.000561	CbGpPWpGaD
Scopolamine—CHRM4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000363	0.00055	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000349	0.00053	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000348	0.000528	CbGpPWpGaD
Scopolamine—CHRM5—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000347	0.000527	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000345	0.000523	CbGpPWpGaD
Scopolamine—CHRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000244	0.000371	CbGpPWpGaD
Scopolamine—CHRM3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000244	0.00037	CbGpPWpGaD
Scopolamine—CHRM2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000241	0.000366	CbGpPWpGaD
